Search results
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Zacks via Yahoo Finance· 10 months agoGalecto’s GLTO mid-stage study evaluating inhaled GB0139 for treatment of idiopathic pulmonary...
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug
Investor's Business Daily· 11 months agoFibroGen reported a second failure for its lead asset on Monday, and FGEN stock crashed to its...
An Unexpected Feat Just Sent Pliant Therapeutics Soaring 35%
Investor's Business Daily· 1 year agoPliant Therapeutics unveiled promising results for a lung disease treatment on Monday, and PLRX...
Clene Stock Falls As Lead Asset Fails To Show Survival, Function Benefit In Amyotrophic Lateral...
Benzinga via Yahoo Finance· 2 years agoClene Inc (NASDAQ: CLNN) shares are falling after the company released topline results from the...
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Benzinga via Yahoo Finance· 2 years agoAlgernon Pharmaceuticals Inc (OTC: AGNPF) has announced topline data showing that it has met the...
Why Pliant Therapeutics Stock Is Skyrocketing This Week
Motley Fool· 1 year agoShares of Pliant Therapeutics (NASDAQ: PLRX) were skyrocketing 61% higher this week as of the market...
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
Zacks via Yahoo Finance· 10 months agoIt was a low-key week for the biotech sector as the earnings season ended and nothing much came from...
Why Are Pliant Therapeutics Shares Rallying Today?
Benzinga via Yahoo Finance· 2 years agoPliant Therapeutics Inc's (NASDAQ: PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary...
How Is COPD Diagnosed?
Health via Yahoo News· 1 year agoMedically reviewed by Susan Russell, MD COPD is diagnosed based on your signs and symptoms, history of smoking and exposure to lung irritants, family...
Zydus Lifesciences concludes subject enrolment in Phase II ALS trial
Clinical Trials Arena via Yahoo Finance· 2 weeks agoZydus Lifesciences has announced the conclusion of subject enrolment in the Phase II clinical trial...